News
-
-
-
-
-
-
-
-
PRESS RELEASE
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Heidelberg Pharma AG and Huadong Medicine receive NMPA approval for Phase Ib/II clinical trial of HDP-101 combination therapy in China. Evaluation of BCMA-targeting ADC in patients with multiple myeloma -
-